~ Apr 09 Dietary Supplements Under Attack - References

References

1. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991 Jan;53(1 Suppl):326S-34S.

2. Gey KF, Moser UK, Jordan P, et al. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr. 1993 May;57(5 Suppl):787S-97S.

3. Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994 Jun 15;139(12):1180-9.

4. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemio-logic Studies of the Elderly. Am J Clin Nutr. 1996 Aug;64(2):190-6.

5. Nyyssonen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ. 1997 Mar 1;314(7081):634-8.

6. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996 May 2;334(18):1156-62.

7. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992 May;3(3):194-202.

8. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008 Nov 12;300(18):2123-33.

9. Gorelik S, Lapidot T, Shaham I, et al. Lipid peroxidation and coupled vitamin oxidation in simulated and human gastric fluid inhibited by dietary polyphenols: health implications. J Agric Food Chem. 2005 May 4;53(9):3397-402.

10. Kanner J, Lapidot T. The stomach as a bioreactor: dietary lipid peroxidation in the gastric fluid and the effects of plant-derived antioxidants. Free Radic Biol Med. 2001 Dec 1;31(11):1388-95.

11. Devaraj S, Tang R, Adams-Huet B, et al. Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr. 2007 Nov;86(5):1392-8.

12. Kiyose C, Muramatsu R, Kameyama Y, Ueda T, Igarashi O. Biodiscrimination of alpha-tocopherol stereoisomers in humans after oral administration. Am J Clin Nutr. 1997 Mar;65(3):785-9.

13. Wilburn EE, Mahan DC, Hill DA, Shipp TE, Yang H. An evaluation of natural (RRR-alpha-tocopheryl acetate) and synthetic (all-rac-alpha-tocopheryl acetate) vitamin E fortification in the diet or drinking water of weanling pigs. J Anim Sci. 2008 Mar;86(3):584-91.

14. Hayton SM, Kriss A, Wade A, Muller DP. The effects of different levels of all-rac- and RRR-alpha-tocopheryl acetate (vitamin E) on visual function in rats. Clin Neurophysiol. 2003 Nov;114(11):2124-31.

15. Hoppe PP, Krennrich G. Bioavailability and potency of natural-source and all-racemic alpha-tocopherol in the human: a dispute. Eur J Nutr. 2000 Oct;39(5):183-93.

16. Lodge JK. Vitamin E bioavailability in humans. J Plant Physiol. 2005 Jul;162(7):790-6.

17. Burton GW, Traber MG, Acuff RV, et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr. 1998 Apr;67(4):669-84.

18. Traber MG. Utilization of vitamin E. Biofactors. 1999;10(2-3):115-20.

19. Blatt DH, Leonard SW, Traber MG. Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition. 2001 Oct;17(10):799-805.

20. Rigotti A. Absorption, transport, and tissue delivery of vitamin E. Mol Aspects Med. 2007 Oct;28(5-6):423-36.

21. Blatt DH, Pryor WA, Mata JE, Rodriguez-Proteau R. Re-evaluation of the relative potency of synthetic and natural alpha-tocopherol: experimental and clinical observations. J Nutr Biochem. 2004 Jul;15(7):380-95.

22. Mustacich DJ, Bruno RS, Traber MG. Vitamin E. Vitam Horm. 2007;76:1-21.

23. Manor D, Morley S. The alpha-tocopherol transfer protein. Vitam Horm. 2007;76:45-65.

24. Morley S, Cecchini M, Zhang W, et al. Mechanisms of ligand transfer by the hepatic tocopherol transfer protein. J Biol Chem. 2008 Jun 27;283(26):17797-804.

25. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr. 2007;27:347-62.

26. Nappo F, De RN, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA. 1999 Jun 9;281(22):2113-8.

27. Valkonen MM, Kuusi T. Vitamin C prevents the acute atherogenic effects of passive smoking. Free Radic Biol Med. 2000 Feb 1;28(3):428-36.

28. Jeserich M, Schindler T, Olschewski M, et al. Vitamin C improves endothelial function of epicardial coronary arteries in patients with hypercholesterolaemia or essential hypertension--assessed by cold pressor testing. Eur Heart J. 1999 Nov;20(22):1676-80.

29. Wilkinson IB, Megson IL, MacCallum H, et al. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol. 1999 Nov;34(5):690-3.

30. Jablonski KL, Seals DR, Eskurza I, Monahan KD, Donato AJ. High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men. J Appl Physiol. 2007 Nov;103(5):1715-21.

31. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology. 2006 Mar;43(3):485-91.

32. Knekt P, Ritz J, Pereira MA, et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 2004 Dec;80(6):1508-20.

33. Rath M, Pauling L. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. Proc Natl Acad Sci USA. 1990 Dec;87(23):9388-90.

34. Pauling L. Are recommended daily allowances for vitamin C adequate? Proc Natl Acad Sci USA. 1974 Nov;71(11):4442-6.

35. Krumdieck C, Butterworth CE, Jr. Ascorbate--cholesterol--lecithin interactions: factors of potential importance in the pathogenesis of atherosclerosis. Am J Clin Nutr. 1974 Aug;27(8):866-76.

36. Ginter E. Cholesterol: vitamin C controls its transformation to bile acids. Science. 1973 Feb 16;179(74):702-4.

37. Ferroni F, Maccaglia A, Pietraforte D, Turco L, Minetti M. Phenolic antioxidants and the protection of low density lipoprotein from peroxynitrite-mediated oxidations at physiologic CO2. J Agric Food Chem. 2004 May 19;52(10):2866-74

38. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000 Dec 20;92(24):2018-23.

39. Christen S, Woodall AA, Shigenaga MK, et al. gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci USA. 1997 Apr 1;94(7):3217-22.

40. Devaraj S, Leonard S, Traber MG, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med. 2008 Mar 15;44(6):1203-8.

41. Reiter E, Jiang Q, Christen S. Anti-inflammatory properties of alpha- and gamma-tocopherol. Mol Aspects Med. 2007 Oct;28(5-6):668-91.

42. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA. 2000 Oct 10;97(21):11494-9.

43. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr. 1985 Jun;115(6):807-13.

44. Wolf G. Gamma-Tocopherol: an efficient protector of lipids against nitric oxide-initiated peroxidative damage. Nutr Rev. 1997 Oct;55(10):376-8.

45. Botti H, BatthyƔny C, Trostchansky A, Radi R, Freeman BA, Rubbo H. Peroxynitrite-mediated alpha-tocopherol oxidation in low-density lipoprotein: a mechanistic approach. Free Radic Biol Med. 2004 Jan 15;36(2):152-62.

46. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086-95.

47. Steinberg D, Carew TE, Fielding C, et al. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 1989 Sep;80(3):719-23.

48. Torres-Rasgado E, Fouret G, Carbonneau MA, Leger CL. Peroxynitrite mild nitration of albumin and LDL-albumin complex naturally present in plasma and tyrosine nitration rate-albumin impairs LDL nitration. Free Radic Res. 2007 Mar;41(3):367-75.

49. Uno M, Kitazato KT, Suzue A, Itabe H, Hao L, Nagahiro S. Contribution of an imbalance between oxidant-antioxidant systems to plaque vulnerability in patients with carotid artery stenosis. J Neurosurg. 2005 Sep;103(3):518-25.

50. Botti H, Trostchansky A, BatthyƔny C, Rubbo H. Reactivity of peroxynitrite and nitric oxide with LDL. IUBMB Life. 2005 Jun;57(6):407-12.

51. Rubbo H, Batthyany C, Radi R. Nitric oxide-oxygen radicals interactions in atherosclerosis. Biol Res. 2000;33(2):167-75.

52. Li D, Saldeen T, Romeo F, Mehta JL. Relative Effects of alpha- and gamma-Tocopherol on Low-Density Lipoprotein Oxidation and Superoxide Dismutase and Nitric Oxide Synthase Activity and Protein Expression in Rats. J Cardiovasc Pharmacol Ther. 1999 Oct;4(4):219-26.

53. Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999 Oct;34(4):1208-15.

54. Mikunis RI, Serkova VK, Shirkova TA. Lipid metabolism and oxidation-reduction properties of blood in patients with arteriosclerotic myocardiosclerosis during treatment with lipoic acid. Vrach Delo. 1976 Mar;(3):39-42.

55. Nickander KK, McPhee BR, Low PA, Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med. 1996;21(5):631-9.

56. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78.

57. Arivazhagan P, Shila S, Kumaran S, Panneerselvam C. Effect of DL-alpha-lipoic acid on the status of lipid peroxidation and antioxidant enzymes in various brain regions of aged rats. Exp Gerontol. 2002 Jun;37(6):803-11.

58. Arivazhagan P, Thilakavathy T, Ramanathan K, Kumaran S, Panneerselvam C. Effect of DL-alpha-lipoic acid on the status of lipid peroxidation and protein oxidation in various brain regions of aged rats. J Nutr Biochem. 2002 Oct;13(10):619-24.

59. Ozgova S, Hermanek J, Gut I. Different antioxidant effects of polyphenols on lipid peroxidation and hydroxyl radicals in the NADPH-, Fe-ascorbate- and Fe-microsomal systems. Biochem Pharmacol. 2003 Oct 1;66(7):1127-37.

60. Thirunavukkarasu V, Anuradha CV. Influence of alpha-lipoic acid on lipid peroxidation and antioxidant defence system in blood of insulin-resistant rats. Diabetes Obes Metab. 2004 May;6(3):200-7.

61. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis. 2004 Dec;14(6):351-7.

62. Singh I, Turner AH, Sinclair AJ, Li D, Hawley JA. Effects of gamma-tocopherol supplementation on thrombotic risk factors. Asia Pac J Clin Nutr. 2007;16(3):422-8.

63. Ros E, Nunez I, Perez-Heras A, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation. 2004 Apr 6;109(13):1609-14.

64. Dietrich M, Traber MG, Jacques PF, Cross CE, Hu Y, Block G. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr. 2006 Aug;25(4):292-9.

65. McLaughlin PJ, Weihrauch JL. Vitamin E content of foods. J Am Diet Assoc. 1979 Dec;75(6):647-65.

66. Tanaka Y, Wood LA, Cooney RV. Enhancement of intracellular gamma-tocopherol levels in cytokine-stimulated C3H 10T1/2 fibroblasts: relation to NO synthesis, isoprostane formation, and tocopherol oxidation. BMC Chem Biol. 2007;72.

67. Gao R, Stone WL, Huang T, Papas AM, Qui M. The uptake of tocopherols by RAW 264.7 macrophages. Nutr J. 2002 Oct 15;12.

68. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007 Oct;32(7):568-72.

69. Pesic S, Radenkovic M, Grbovic L. Endothelial dysfunction: mechanisms of development and therapeutic options. Med Pregl. 2006 Jul-Aug;59(7-8):335-41.

70. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 Aug 6;106(6):653-8.

71. Targonski PV, Bonetti PO, Pumper GM, et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003 Jun 10;107(22):2805-9.

72. von Mering GO, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004 Feb 17;109(6):722-5.

73. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 Nov 27;104(22):2673-8.

74. Chan SY, Mancini GB, Kuramoto L, et al. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003 Sep 17;42(6):1037-43.

75. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003 Oct 28;108(17):2093-8.

76. Ali ZA, Bursill CA, Douglas G, et al. CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis. Circulation. 2008 Sep 30;118(14 Suppl):S71-7.

77. McCarty MF. Gamma-tocopherol may promote effective no synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses. 2007;69(6):1367-70.

78. de Nigris F, Balestrieri ML, Williams-Ignarro S, et al. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. 2007 Aug;17(1):50-4.

79. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA. 1991 Mar 1;88(5):1646-50.

80. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA. 1990 Jun;87(12):4879-83.

81. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med. 1997;18(Suppl):S85-103.

82. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 Jun 26;1126(3):247-54.

83. Kontush A, Hubner C, Finckh B, Kohlschutter A, Beisiegel U. Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein. Biochim Biophys Acta. 1995 Sep 14;1258(2):177-87.

84. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J Biol Chem. 1995 Mar 17;270(11):5756-63.

85. Tribble DL, van den Berg JJ, Motchnik PA, et al. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA. 1994 Feb 1;91(3):1183-7.

86. Block G, Jensen CD, Dalvi TB, et al. Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med. 2009 Jan 1;46(1):70-7.

87. Afkhami-Ardekani M, Shojaoddiny-Ardekani A. Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients. Indian J Med Res. 2007 Nov;126(5):471-4.

88. Maras JE, Bermudez OI, Qiao N, et al. Intake of alpha-tocopherol is limited among US adults. J Am Diet Assoc. 2004 Apr;104(4):567-75.

89. Puri V, Chaudhry N, Tatke M, Prakash V. Isolated vitamin E deficiency with demyelinating neuropathy. Muscle Nerve. 2005 Aug;32(2):230-5.

90. Schuelke M, Finckh B, Sistermans EA, et al. Ataxia with vitamin E deficiency: biochemical effects of malcompliance with vitamin E therapy. Neurology. 2000 Nov 28;55(10):1584-6.

91. Tanyel MC, Mancano LD. Neurologic findings in vitamin E deficiency. Am Fam Physician. 1997 Jan;55(1):197-201.

92. Sokol RJ. Vitamin E deficiency and neurologic disease. Annu Rev Nutr. 1988;8:351-73.

93. Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurologic disorder from vitamin E deficiency. Neurology. 1986 Jul;36(7):917-21.

94. Laplante P, Vanasse M, Michaud J, Geoffroy G, Brochu P. A progressive neurological syndrome associated with an isolated vitamin E deficiency. Can J Neurol Sci. 1984 Nov;11(4 Suppl):561-4.

95. Available at: http://www.medpagetoday.com/MeetingCoverage/AHA/11684. Accessed January 20, 2009.

96. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008 Nov 19;100(22):1581-91.

97. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61.

98. Neuhouser ML, Sorensen B, Hollis BW, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr. 2008 Jul;88(1):133-9.

99. Kemper KJ, Hood KL. Does pharmaceutical advertising affect journal publication about dietary supplements? BMC Complement Altern Med. 2008;811.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.